Amgen's Trading Volume Plummets 58.98% to $493 Million Ranking 149th Amid Clinical Trial Setbacks and Regulatory Hurdles

On April 21, 2025, Amgen's trading volume was $493 million, a significant decrease of 58.98% compared to the previous day, ranking 149th in the day's stock market trading volume. Amgen's stock price fell by 1.30%, marking the third consecutive day of decline, with a total decrease of 7.32% over the past three days.

Amgen has recently faced challenges in its clinical trials for its experimental drug, AMG 133, which is designed to treat severe asthma. The company announced that the Phase 2 trial did not meet its primary endpoint, leading to a setback in its development plans. This news has raised concerns among investors about the future prospects of the drug and its potential impact on Amgen's revenue.

Additionally, Amgen's partnership with a major pharmaceutical company to develop a new treatment for Alzheimer's disease has been put on hold due to regulatory hurdles. This delay has further dampened investor sentiment, as the collaboration was seen as a key growth driver for the company. The uncertainty surrounding the partnership has led to increased volatility in Amgen's stock price.

Despite these challenges, Amgen remains optimistic about its long-term prospects. The company has a strong pipeline of innovative drugs in development, including treatments for cancer, cardiovascular disease, and inflammatory disorders. Amgen's management has reiterated its commitment to investing in research and development to drive future growth.